Purpose: The aim of this study was to evaluate the quality of care and interdisciplinary cooperation in the palliative treatment of @entity14 ( @entity14 ), including the associated costs. @entity1 and Methods: 103 @entity1 were enrolled from 13 institutions to reflect the existing clinical treatment reality and costs of palliative @entity14 treatment. We present the clinical outcome of the @entity1 and compare the results obtained in the 3 centers with double-figure recruitment numbers (centers A, B, and C). Results: First-line treatment with @entity1487 monotherapy was applied in exceptional cases. The regular treatment method comprised either an irinotecan- (30%) or an @entity901 -based regimen (32%). Biological agents were added to the treatment of 33 @entity1 (32%). The median overall survival (OS) of the total @entity1 collective was 25 months. The OS differed significantly in 2 out of the 3 centers, ranging between 27 and 11 months. Secondary metastasis resections were performed in 26% of the total @entity1 collective. The center with the most favorable outcome results also had the lowest costs for palliative treatment and care, including the lowest drug costs. Conclusion: A combined chemotherapy treatment was the rule. Concerning biological agents, a significant lack of their application in first-line treatment and the quality of interdisciplinary cooperation have to be addressed.    2014 S. Karger AG, Basel.

Palliative Treatment of XXXX with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil'] @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal Cancer']
